(i) SFV/IFNγ-induced macrophage reprogramming may synergise with other TME-targeted therapies, such as TLR agonists or CTL-activating agents (checkpoint inhibitors), to achieve durable anti-tumour responses. The gene discussed is IFNG; the disease is neoplasm.